Cagrilintide Dosage: How It's Used

If you typed “cagrilintide dosage” into a search bar, you were almost certainly looking for a number — a milligram amount, a frequency, maybe a titration schedule you could follow. This page won’t give you that, and not because the information is being withheld. It’s because, in 2026, a standalone cagrilintide dose is not a real thing you can act on. The single validated dose lives somewhere you can’t get at it, the alternative number people quote belongs to an abandoned research path, and copying either one into a gray-market vial is unsafe in a way that’s specific to this compound. Understanding why is far more protective than any chart.

The dose exists — but it’s locked inside a combination pen

Cagrilintide does have a validated, real-world dose. It’s 2.4 mg once weekly. The problem is where that dose lives: it exists only as one half of CagriSema, Novo Nordisk’s investigational fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, delivered as a single once-weekly subcutaneous injection from one pre-filled pen. The two molecules are co-formulated — combined in the same solution, in the same device — and the patient never separates them, never measures them, and never sees a freestanding “cagrilintide amount.” The pen is the dose, and the dose is a partnership.

That matters because the number people lift from CagriSema and relabel as “the cagrilintide dose” was never a standalone instruction. It’s the cagrilintide share of a combination product, validated only in the presence of semaglutide and only inside an engineered fixed-dose device. Stripping the 2.4 mg out, dropping the semaglutide, and treating the remainder as a self-administration recipe is a category error: you’re taking a co-formulation figure and pretending it’s a monotherapy protocol.

And CagriSema isn’t even on the market. Novo Nordisk submitted its New Drug Application to the FDA in December 2025, based on the REDEFINE Phase 3 program, with a decision expected in 2026. As of this writing it is not approved in the US or EU. So the one place the validated number lives is itself a product you can’t buy with a prescription yet — and when you can, it’ll be a combination pen, not a vial of cagrilintide you dose by hand.

Note: A fixed-dose combination is the opposite of a stack you assemble yourself. The whole engineering point is that the measuring, the ratio, and the timing are decided once, at the factory, and removed from the user’s hands. A gray-market vial undoes all of that and hands the riskiest steps back to you.

The “alternative” number is an abandoned branch

There’s a second figure floating around: cagrilintide used alone. This one has a genuine pedigree — Novo Nordisk ran a Phase 2 dose-finding trial of once-weekly cagrilintide monotherapy in adults with overweight or obesity. The trial used a dose-escalation period over the first few weeks and then a maintenance period across roughly half a year, with participants self-injecting subcutaneously once a week. So unlike some research peptides that have no human dosing record at all, cagrilintide-alone was actually studied in a structured, escalating, once-weekly fashion.

But here’s the decisive fact: Novo Nordisk looked at that monotherapy data and chose not to develop a standalone cagrilintide product. It took the combination forward instead. The standalone path is, in practical terms, a road not taken — there is no standalone cagrilintide NDA, no approved monotherapy product, and no monotherapy label. So the monotherapy “dose” you’ll see quoted is a figure from a completed dose-finding study that the manufacturer itself declined to turn into a usable medicine. Describing the shape of that trial — escalate over a few weeks, hold a maintenance dose, inject once weekly — tells you how the compound was investigated. It does not give you a protocol, because the entity that ran the study decided the protocol wasn’t worth commercializing on its own.

That’s the trap at the center of this page: cagrilintide’s dosing question has two answers, and both are dead ends for a self-doser. One number is a combination figure that doesn’t survive being separated from its partner. The other is a monotherapy figure that its own developer abandoned. Neither was ever meant to be drawn up by hand at home.

Why there’s no clinician-set route either

With many medications, the honest answer to “what’s my dose?” is “whatever a prescriber decides for you, then adjusts.” That’s the correct framing for dosing in general — individualized, set by a licensed clinician, titrated against your response and monitoring. But for cagrilintide specifically, even that route is closed in 2026, and it’s worth being precise about why.

A legitimate prescription presumes two things: a clinician who can lawfully write it and a pharmacy that can lawfully fill it. Cagrilintide has neither leg. It isn’t FDA-approved, so there’s no approved product to dispense. And — unlike some research peptides that have a contested compounding pathway — the FDA does not permit cagrilintide to be compounded. It’s a proprietary, patent-protected investigational molecule that isn’t on the bulk-substance lists a 503A or 503B pharmacy would need to make it. So there is no compounding pharmacy at the end of the prescription. A prescriber genuinely cannot set you a monitored, dispensed cagrilintide dose through normal channels, because the dispensing channel doesn’t exist.

The only legitimate way to receive cagrilintide under medical supervision today is enrollment in a registered clinical trial, where the dose, the product, and the monitoring are all controlled. Outside that, there is no lawful dose-setting route — which means any service “prescribing” cagrilintide is, in practice, routing you to a research-only vial dressed up as a clinical product.

The gray-market vial reintroduces every removed risk

Suppose someone ignores all of the above and buys a vial labeled “cagrilintide” online. The danger here is unusually concrete, and it’s worth naming plainly.

A research-only vial is sold as a chemical, not a medicine. Its actual concentration, identity, and purity are not verified to the standard a dispensed drug would be. Independent testing of gray-market peptides repeatedly turns up products that are underdosed, overdosed, mislabeled, degraded, or not the advertised peptide at all. So even if you copied a “correct” number perfectly, you’d be applying correct arithmetic to an unknown quantity in an unknown solution. The right dose of the wrong product is still the wrong dose — the bottle is the risk, not the math.

Worse, this is precisely the compound where a fixed-dose pen was engineered to remove the measuring step. CagriSema’s entire delivery design exists so the patient never reconstitutes, never draws up, never converts units, never gets the ratio wrong. Buying a vial throws all of that away and hands the most error-prone tasks back to a person with no device, no verified concentration, and no oversight. You are not approximating the trial — you are doing the one thing the trial’s delivery system was built to prevent.

There’s a tell worth remembering: any page that pairs a confident cagrilintide “dosage” with reconstitution math, unit-conversion calculators, and a “buy” button is not describing a medical decision. It’s writing self-injection instructions for an unregulated injectable. The presence of a dosing chart next to a vendor link is itself the warning sign.

What “dosing” actually is — and the legitimate alternative

Strip away the spreadsheet and a dose is the last and least transferable output of a chain of clinical judgments: which compound, for which person, toward which goal, using which verified product, with which monitoring. An internet protocol keeps only the final number and deletes every input — the evaluation, the verified product, the ability to adjust, the follow-up. For cagrilintide it deletes even more, because there’s no approved product and no lawful pharmacy to anchor the number to in the first place.

If what you actually want is a weight-loss medication you can use now, with a real dose set and monitored by a clinician, the honest redirect is to the FDA-approved GLP-1 medicines. Semaglutide and tirzepatide brands have validated, individualized, prescriber-set dosing, a lawful dispensing channel, and an established safety-monitoring framework — everything cagrilintide’s gray market is missing. A licensed provider evaluates you, sets a starting point, and titrates against your tolerance and response. That is what a “dose” is supposed to be, and it’s available through legitimate channels today in a way standalone cagrilintide simply is not.

The regulatory picture can shift — CagriSema’s FDA decision is pending and the landscape is moving — so treat everything here as current as of the date above. But the core logic won’t change with a single approval: even if CagriSema clears the FDA, it will arrive as a fixed-dose combination pen the patient never measures, not as a standalone cagrilintide vial you dose yourself. The number you were searching for was never going to be yours to set.